September 15, 2025
The Infusion Providers Alliance (IPA) submitted comments today to the Centers for Medicare and Medicaid Services (CMS) on the Calendar Year 2026 Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule. IPA supports proposals to address site-of-service payment disparities that exist between independent, non-hospital physician offices and infusion clinics and hospital-owned outpatient sites, where hospitals currently benefit from higher payments and significant drug acquisition advantages for administering identical Part B drugs.
IPA’s comments highlight support for two proposed policies:
- IPA supports CMS’s proposal to control unnecessary and inflated costs at “excepted off-campus provider-based sites,” with respect to Part B drug administration.
- IPA supports CMS’s proposal to conduct a survey of 340B hospitals’ drug acquisition costs to determine more appropriate Medicare payment rates.
IPA also emphasized that long-term site-of-service reform must ensure non-hospital infusion providers are adequately funded and supported so they have the incentive and capacity to take on additional patients who may be turned away from hospitals. Protecting and strengthening these care settings is essential to preserving patient access and affordability.
Read IPA’s full comment letter to CMS here.
About the Infusion Providers Alliance
The Infusion Providers Alliance (IPA) is committed to protecting the integrity of the provider-patient relationship by empowering providers and patients to choose the most appropriate treatment together. We advocate for policies that ensure timely and adequate patient access to high quality care in IPA members’ convenient, community-based, non-hospital settings. IPA members operate over 1,000 in-office or stand-alone ambulatory infusion centers across 43 states nationwide, delivering value to the health care system and improved outcomes to patients.
All inquiries should be emailed to ewarren@infusionprovidersalliance.org.